SIRPD

Across TCGA pan-cancer cohorts, SIRPD RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated SIRPD data layer compared with 3 for mutation status.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SIRPD RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated SIRPD expression acts as an unfavorable survival marker, although some lineages such as CESC and SKCM show a favorable association.

CESC, SKCM, and KICH are the cancer types where SIRPD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Tertile	All	0.898	0.744	<.001	108	view →
SKCM	OS	Tertile	All	0.456	0.275	<.001	79	view →
KICH	OS	Tertile	II,III,IV	0.678	0.970	.001	48	view →
UVM	DFS	Tertile	All	0.361	0.712	.002	39	view →
LGG	OS	Median	All	0.370	0.524	<.001	35	view →
ACC	OS	Tertile	IV	0.278	0.628	.004	20	view →
KIRC	DFS	Quartile	All	0.715	0.833	.005	16	view →
HNSC	DFS	Tertile	III,IV	0.752	0.627	.021	14	view →
SARC	OS	Median	All	0.831	0.672	<.001	14	view →
ESCA	DFS	Tertile	IV	0.216	0.542	.021	12	view →
LIHC	DFS	Median	III,IV	0.570	0.242	.005	9	view →
MESO	DFS	Tertile	II,III,IV	0.359	0.666	.019	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

SIRPD–CESC (DFS)

Open the CESC breakdown →